StreetAlpha.app
Home › Stocks › SEPN

Septerna, Inc. (SEPN)

Healthcare
$38.61
▼ −1.51%
LAST CLOSE · NOV 20

Septerna is a clinical stage biotech company developing oral small molecule medicines that target G protein coupled receptors. It last closed at $38.61 on Nov 20, down 1.51% on the day. The next earnings report for SEPN is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, SEPN reported EPS of -$0.57 on revenue of $18.9M, with revenue down 12.2% from a year ago. Over its last 8 reports the stock moved an average of 5.6% the session after earnings. Over the last 12 months SEPN insiders bought $0 of stock on the open market and sold $74.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is SEPN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SEPN.

Key Stats

Last 12 months
Results
Revenue
$96.3M
+336.7% vs a year ago
Net income
−$59.0M
−61.3% margin
EPS (diluted)
−$1.30
−109.5% vs a year ago
Free cash flow
−$77.6M
−80.6% margin
Valuation
Market cap
$1.8B
47.5M shares
P/E
–
No P/E while losing money
Price to sales
19.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$167.1M
At Sep 30
Shareholder equity
$427.9M
Shares outstanding
47.5M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $151K$151KFY2023FY2024: $1.1M$1.1MFY2024FY2025: $46.0M$46.0MFY2025

From SEPN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · After the close
Reported EPS
-$0.57
Quarter ended Sep 2026
Year ago EPS
$0.18
−416.7% on a GAAP basis
Revenue
$18.9M
−12.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $14.61Dec '24Mar 2025: -$0.49Mar '25Jun 2025: -$0.56Jun '25Sep 2025: $0.18Sep '25Dec 2025: -$0.24Dec '25Mar 2026: -$0.19Mar '26Jun 2026: -$0.29Jun '26Sep 2026: -$0.57Sep '26Latest -$0.57
Revenue by quarter
Dec 2024: $212,000Dec '24Mar 2025: $219,000Mar '25Jun 2025: $119,000Jun '25Sep 2025: $21.5MSep '25Dec 2025: $24.1MDec '25Mar 2026: $26.5MMar '26Jun 2026: $26.7MJun '26Sep 2026: $18.9MSep '26Latest $18.9M
How SEPN moved after its last 8 reports
Average move the session after a report ±5.6%
Nov 9, 2026After the close+3.1%
Aug 10, 2026After the close+22.9%
May 11, 2026After the close+5.4%
Mar 9, 2026After the close−3.6%
Nov 10, 2025Time not announced−2.2%
Aug 11, 2025After the close−2.5%
May 15, 2025After the close−2.8%
Mar 27, 2025Time not announced+2.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SEPNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SEPN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SEPN

Technical Analysis

SEPN · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 15% below its 20 day and 5% below its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the swing low (Oct 26) at $38.39, and the nearest resistance the swing high (Oct 9) at $38.73.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 7.7%/day
Key levels
$53.3452 week high+38.2%
$44.2520 day average+14.6%
$40.6850 day average+5.4%
$39.59Pivot R1+2.5%
$39.21100 day average+1.6%
$38.91Pivot+0.8%
$38.73Swing high (Oct 9)+0.3%
$38.61Last close
$38.39Swing low (Oct 26)−0.6%
$37.93Pivot S1−1.8%
$33.50200 day average−13.2%
$22.7852 week low−41.0%
Indicators
RSI (14)39.96Weak, oversold below 30Neutral
MACD-0.21Below its signal lineBearish
Stochastic2.8Near the bottom of its rangeOversold
ADX (14)15.4No clear trend
Williams %R-97.5Oversold below −80, overbought above −20Oversold
CCI (20)-119.6Oversold below −100, overbought above 100Oversold
Rate of change−21.0%Change over 10 sessionsBearish
ATR (14)$2.96Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for SEPN

What happened before

See how SEPN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for SEPNHow many large options trades hit SEPN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SEPN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲111 buying vs 54 selling
  • ▲Held by funds +4.0 pts
  • ▲Funds holding +17
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding173156+10.9%
In funds' top 1084+100.0%
Held by funds103.8%99.8%+4.0 pts
New / increased32 / 7946 / 49+16.8%
Reduced / sold out38 / 1632 / 16+12.5%
Put/call ratio0.740.56+30.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SEPN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SEPN Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$74.3M18 sales · 7 insiders
15% of the selling was under pre-arranged trading plans.
2026-02 sold $116K2026-03 sold $2.0M2026-04 sold $97K2026-05 sold $355K2026-06 sold $1.0M2026-07 sold $251K2026-08 sold $64.7M2026-09 sold $126K2026-10 sold $150K2026-11 sold $5.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Gil M LabrucherieCFOSale plan20,000$41.62$832K
Nov 12Jeffrey FinerCEOSale plan18,500$43.62$807K
Nov 11Alan EzekowitzDirectorSale plan81,820$48.09$3.9M
Oct 15Elizabeth BhattPresident and COOSale plan4,000$37.41$150K
Sep 1Daniel D. LongSVP, Drug DiscoverySale plan3,333$37.83$126K
Aug 12Ra Capital Management, L.P.DirectorSale1,493,000$42.50$63.5M
Every insider buy and sale for SEPN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SEPN insider trades →

From SEC Form 4 filings by SEPN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SEPN is in one of them and how their past SEPN trades turned out.

SEPN in the AI portfolios
Loading…

SEPN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SEPN in an article yet. Here's the latest on the wider market.

SEPN in the news

About Septerna

Septerna is a clinical stage biotechnology company based in South San Francisco, California. It uses its Native Complex Platform to discover oral small molecule medicines that act on G protein coupled receptors, a large family of proteins that help control many processes in the body. Its pipeline is focused on endocrine diseases, immune and inflammatory conditions, and metabolic diseases. The company aims to develop these medicines for patients with significant unmet medical needs.

Headquarters
South San Francisco, CA